Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon’s Nuvigil User-Fee Date Extended

This article was originally published in The Pink Sheet Daily

Executive Summary

The company still expects to bring the excessive sleepiness therapy to market by mid-2006.

You may also be interested in...



Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials

Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.

Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials

Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.

Gabitril Generalized Anxiety Disorder Filing Anticipated Mid-Year

Cephalon expects the results of Phase III studies supporting the anti-seizure medication for generalized anxiety will be available in Q2.

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel